The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; Bristol-Myers Squibb; Dendreon; Exelixis; Janssen; Novartis; Pfizer; Tempus
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Wanling Xie
No Relationships to Disclose
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Seattle Genetics/Astellas (Inst)
 
David A. Braun
Honoraria - LM Education/Exchange Service
Consulting or Advisory Role - Adept Field Solutions; Blueprint Partnership; Bristol-Myers Squibb; Charles River Associates; Dedham Group; Defined Health; Insight Strategy; Octane Co.; Schlesinger Associates; Slingshot Insights; Trinity Group
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Xiao X. Wei
Honoraria - OncLive
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Christos Kyriakopoulos
Consulting or Advisory Role - Exelixis
Speakers' Bureau - The France Foundation
Research Funding - Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; TTC Oncology
Travel, Accommodations, Expenses - Newlink Genetics
 
Benjamin Louis Maughan
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Peleton; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Tracy L Rose
Research Funding - Bristol-Myers Squibb; GeneCentric; Merck; Roche/Genentech; X4 Pharma
 
Walter Michael Stadler
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; CVS Caremark; Eisai; Merck; Pfizer; Roche/Genentech; Sotio
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst)
Other Relationship - American Cancer Society; UpToDate
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Lauren C Harshman
Employment - Surface Oncology
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech; Jounce Therapeutics; Merck; Michael J. Hennessy Associates; Novartis; Ology Medical Education; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Endocyte (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Genentech
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel